


Claims:

1. The use of a lipopeptide or lipoprotein of the structure (I)

5



where

- 10 R_1 and R_2 , which may be identical or different, are C_{7-25} -alkyl, C_{7-25} -alkenyl or C_{7-25} -alkynyl, X is S, O or CH_2 , R_3 and R_4 are independently of one another H or methyl and
- 15 Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used, and the asymmetric carbon atom marked with * as the absolute R configuration, according to the
- 20 Cahn-Ingold-Prelog rule, when X is S (sulfur), as mucosal adjuvant in therapeutic or prophylactic vaccination via the mucous membranes.


- 25 2. The use as claimed in claim 1, characterized in that the amino acid sequence Y is preferably selected from.

- a) GQTNT
 b) SKKKK
 c) GNNDESNISFKEK
 30 d) GQTDNNSSQSAAPGSGTTNT,

3. The use as claimed in claim 1 or 2, characterized in that the lipoprotein or lipopeptide of structure (I) is an S-[2,3-

bispalmitoyloxy(2R)propyl]cysteiny]l-peptide, where the peptide is a physiologically tolerated amino acid sequence which consists of 1 to 25 amino acid residues and is preferably not immunogenic in the species used.

4. The use as claimed in any of claims 1 to 3, characterized in that the mucosal adjuvant is present in a preparation with the actual vaccine component which is intended for intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral administration or administration into the milk ducts of the female breast.
5. The use as claimed in any of claims 1 to 3, characterized in that the mucosal adjuvant is present in a kit for coadministration with a vaccine into the milk ducts of the female breast, by the intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral route.
6. The use of a lipopeptide or lipoprotein of the general structure (I)



where

R₁ and R₂, which may be identical or different, are C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl or C₇₋₂₅-alkynyl,

X is S, O or CH₂,

R₃ and R₄ are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,
5 and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur), excepting an S-(2,3-diacyloxypropyl)cysteine-peptide of the sequence DhcGNNDESNISFKEK, where N-terminally the amino acids at positions 2 and,
10 where appropriate, 3 are absent, and/or C-terminally 1 to 2 amino acids may be deleted,

as adjuvant in a non-mucosal vaccination.

15

7. The use as claimed in any of claims 1 to 6, characterized in that the lipopeptide or lipoprotein is present in a preparation with at least one further adjuvant and/or antigen.

20

8. The use as claimed in any of claims 1 to 7, characterized in that the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

25

9. The use as claimed in any of claims 1 to 8, characterized in that the lipopeptide or lipoprotein is administered together with one or more anti-inflammatory, antiangiogenic, cytotoxic
30 or immunomodulatory substances or ligands or with antibodies, or is present with these in a preparation.

10. The use as claimed in any of claims 1 to 9,
35 characterized in that the lipopeptide or lipoprotein is present in a preparation which comprises further additives and excipients, in particular preservatives or stabilizers.

11. The use as claimed in any of claims 1 to 10,
characterized in that the vaccine which is
accompanied by the adjuvant, in the form of
5 peptides, proteins, DNA, polysaccharides,
glycolipids or glucoproteins.